Insider Selling: Cellebrite DI (NASDAQ:CLBT) Insider Sells $285,625.71 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) insider Thomas Hogan sold 25,299 shares of Cellebrite DI stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total value of $285,625.71. Following the completion of the transaction, the insider owned 765,249 shares in the company, valued at $8,639,661.21. The trade was a 3.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Cellebrite DI Trading Up 5.8%

NASDAQ:CLBT traded up $0.67 on Thursday, hitting $12.29. 2,943,165 shares of the stock were exchanged, compared to its average volume of 2,277,598. The stock has a market cap of $3.07 billion, a PE ratio of 55.87, a PEG ratio of 1.73 and a beta of 1.18. The stock has a fifty day moving average of $14.19 and a 200-day moving average of $13.80. Cellebrite DI Ltd. has a fifty-two week low of $9.58 and a fifty-two week high of $19.98.

Institutional Trading of Cellebrite DI

Several large investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Cellebrite DI by 16.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock worth $3,362,000 after acquiring an additional 24,881 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Cellebrite DI by 16.2% in the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock worth $5,029,000 after acquiring an additional 43,898 shares in the last quarter. Invesco Ltd. boosted its holdings in Cellebrite DI by 6.4% in the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after purchasing an additional 209,473 shares during the last quarter. First Trust Advisors LP acquired a new stake in Cellebrite DI during the 2nd quarter valued at approximately $341,000. Finally, Marshall Wace LLP acquired a new stake in Cellebrite DI during the 2nd quarter valued at approximately $4,472,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on CLBT. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th. JPMorgan Chase & Co. reduced their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. DA Davidson decreased their price objective on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Weiss Ratings lowered shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, August 13th. Finally, Lake Street Capital cut their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average target price of $16.70.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.